1Y Close · As of Aug 26, 2026
ABL Bio operates in the Pharmaceuticals sector.
Legal name: ABL Bio Inc.
In fiscal year 2025, ABL Bio (298380) reported revenue of 79.3 billion KRW, up 137.6% from 33.4 billion KRW a year earlier.
Operating profit was -40.4 billion KRW and net income was -37.9 billion KRW in the same year.
As of the Aug 26, 2026 close, the market capitalization was 4.18 trillion KRW, with a P/B of 26.65.
These figures can be verified in the DART filing (receipt no. 20260312000744).
Financials
| Year | Rev | Op Inc | Net Inc |
|---|---|---|---|
| 2025 | 79.3B | -40.4B | -37.9B |
| 2024 | 33.4B | -59.4B | -55.5B |
| 2023 | 65.5B | -2.6B | -2.6B |
| 2022 | 67.3B | 908M | 3.2B |
| 2021 | 5.3B | -52.3B | -43.6B |
Recent Filings
Stock Option Grant Report
Semi-Annual Report (2026.06)
Large Shareholding Report (General)
Checks
1 of 8 checked items currently applicable.
Market Cap & Price: Market cap is above the delisting threshold.
Administrative Designation: No administrative designation criteria met.
Audit Opinion: Audit opinion: Unqualified (clean).
Convertible Bonds: No convertible bonds outstanding.
Treasury Stock: No treasury stock filings.
Embezzlement & Litigation: No embezzlement or litigation filings in the last 180 days.
Major Shareholder Change: No major shareholder changes in the last 180 days.
Market Action: No market actions recorded in the last 180 days.
Recent Filings
| Date | Filing |
|---|---|
| 2026-08-26 | Stock Option Grant Report |
| 2026-08-11 | Semi-Annual Report (2026.06) |
| 2026-08-04 | Large Shareholding Report (General) |